Insider Selling: Roivant Sciences (NASDAQ:ROIV) Director Sells $196,236.12 in Stock

by · The Markets Daily

Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) Director Melissa Epperly sold 4,938 shares of the stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $39.74, for a total transaction of $196,236.12. Following the completion of the transaction, the director owned 9,900 shares of the company’s stock, valued at approximately $393,426. This represents a 33.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roivant Sciences Stock Performance

NASDAQ ROIV traded up $0.41 during trading on Thursday, reaching $39.98. 7,603,971 shares of the company traded hands, compared to its average volume of 6,302,233. The stock’s 50 day moving average price is $36.04 and its two-hundred day moving average price is $31.89. The company has a market cap of $28.88 billion, a price-to-earnings ratio of -75.43 and a beta of 1.12. Roivant Sciences Ltd. has a 1-year low of $14.50 and a 1-year high of $42.50.

Roivant Sciences (NASDAQ:ROIV – Get Free Report) last issued its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%.The business had revenue of $1.44 million during the quarter, compared to analysts’ expectations of $2.06 million. Equities research analysts expect that Roivant Sciences Ltd. will post -2 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Bank of America reiterated a “neutral” rating on shares of Roivant Sciences in a research report on Friday, July 31st. Guggenheim raised their target price on Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a research note on Wednesday, September 9th. Leerink Partners set a $42.00 price target on Roivant Sciences in a report on Thursday, May 21st. UBS Group set a $55.00 price target on shares of Roivant Sciences in a research report on Wednesday, September 9th. Finally, Citigroup raised their price objective on shares of Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a research report on Monday, August 10th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $41.42.

Get Our Latest Analysis on Roivant Sciences

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Allspring Global Investments Holdings LLC acquired a new position in Roivant Sciences in the first quarter valued at approximately $3,957,000. Jefferies Financial Group Inc. acquired a new stake in Roivant Sciences during the 4th quarter worth $76,272,000. Bank of America Corp DE grew its holdings in Roivant Sciences by 8.0% during the 1st quarter. Bank of America Corp DE now owns 3,163,821 shares of the company’s stock worth $87,638,000 after acquiring an additional 235,493 shares during the period. Nicholas Investment Partners LP raised its position in shares of Roivant Sciences by 13.9% during the 4th quarter. Nicholas Investment Partners LP now owns 279,856 shares of the company’s stock valued at $6,073,000 after acquiring an additional 34,235 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Roivant Sciences during the 4th quarter valued at $112,750,000. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

(Get Free Report)

Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with significant unmet medical needs. The company concentrates on areas including immunology, dermatology, oncology and other specialty conditions, using a combination of internally developed programs, external licensing and strategic acquisitions.

Roivant organizes many of its drug-development activities through subsidiary companies known as “Vants.” These businesses are designed to advance individual therapeutic programs or groups of related assets, while Roivant provides operational, scientific and strategic support.

Further Reading